Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on respiratory burst activity of neutrophils in patients with myelodysplastic syndromes
- PMID: 7679062
- PMCID: PMC1554685
- DOI: 10.1111/j.1365-2249.1993.tb05900.x
Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on respiratory burst activity of neutrophils in patients with myelodysplastic syndromes
Abstract
The superoxide (O2-)-releasing capacity in response to N-formyl-methionyl-leucyl-phenylalanine (FMLP) and the priming effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and granulocyte-macrophage colony-stimulating factor (rhGM-CSF) on FMLP-induced O2- release were investigated in neutrophils from 14 patients with myelodysplastic syndromes (MDS). The O2(-)-releasing capacity in MDS neutrophils varied from patient to patient. As compared with normal neutrophils, the O2(-)-releasing capacity in MDS neutrophils was increased in 9/14 patients, normal in three patients and decreased in two patients. There was no close relationship between the O2(-)-releasing capacity and the peripheral blood neutrophil count or the plasma concentration of C-reactive protein. The priming of neutrophils by rhG-CSF was not observed in five patients, whereas rhGM-CSF primed neutrophils from all patients. The priming effect of rhGM-CSF was consistently greater than that of rhG-CSF in each patient. The intravenous administration of rhG-CSF (300 micrograms/body) to two MDS patients showed an increase in the peripheral blood neutrophil count and enhancement of neutrophil O2- release. These findings demonstrate that the neutrophil O2(-)-releasing capacity in MDS varies from patient to patient and is not always impaired, and that rhGM-CSF is able to prime neutrophils which never respond to rhG-CSF.
Similar articles
-
Increased respiratory burst activity of neutrophils in patients with aplastic anemia: effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor.Exp Hematol. 1992 Oct;20(9):1090-3. Exp Hematol. 1992. PMID: 1281785
-
Granulocyte and granulocyte-macrophage colony-stimulating factors exert differential effects on neutrophil platelet-activating factor generation and release.Immunology. 1994 May;82(1):51-6. Immunology. 1994. PMID: 7519173 Free PMC article.
-
The effect of three human recombinant hematopoietic growth factors (granulocyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor, and interleukin-3) on phagocyte oxidative activity.Blood. 1993 Apr 1;81(7):1863-70. Blood. 1993. PMID: 7681704
-
Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on the bactericidal functions of neutrophils.Curr Opin Hematol. 1997 May;4(3):183-90. doi: 10.1097/00062752-199704030-00005. Curr Opin Hematol. 1997. PMID: 9209834 Review.
-
Hematopoietic growth factors for the treatment of myelodysplastic syndromes.Leuk Lymphoma. 1998 Feb;28(5-6):491-500. doi: 10.3109/10428199809058356. Leuk Lymphoma. 1998. PMID: 9613978 Review.
Cited by
-
Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia.Drugs. 1994 Nov;48(5):731-60. doi: 10.2165/00003495-199448050-00007. Drugs. 1994. PMID: 7530630 Review.
-
Constitutive activation of SHP2 protein tyrosine phosphatase inhibits ICSBP-induced transcription of the gene encoding gp91PHOX during myeloid differentiation.J Leukoc Biol. 2008 Mar;83(3):680-91. doi: 10.1189/jlb.0807514. Epub 2007 Dec 18. J Leukoc Biol. 2008. PMID: 18089853 Free PMC article.
-
Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study.Cancer Immunol Immunother. 2015 Feb;64(2):237-47. doi: 10.1007/s00262-014-1628-6. Epub 2014 Oct 29. Cancer Immunol Immunother. 2015. PMID: 25351719 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous